- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
LEISHMANIASIS DRUG
AEterna Laboratories reported recently the results of a phase III trial evaluating its drug Impavido (miltefosine) for the treatment of cutaneous leishmaniasis, showing that patients taking Impavido had a 220-percent better cure rate compared with those in a placebo group.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Case 2: Poorly Managed GPP Flares and Effisayil 2 Trial Results
Case 1: Experts on a GPP Emergency Case and Effisayil 1 Trial Results
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Determining Appropriate Candidates for JAK Inhibitor Therapy
Enhancing Treatment Adherence: The Impact of Convenience and Topical JAK Inhibitors on Real-World Outcomes
Potential Role of Ruxolitinib Cream in Managing Pediatric Atopic Dermatitis: A Perspective on Use in Ages 2–11
The Need for Nonsteroidal Alternatives in Long-Term Atopic Dermatitis Care: A Focus on Pediatric Patients
Parental Frustrations with Current Treatment Options for Children with Atopic Dermatitis
Navigating Patient Factors When Deciding Treatment for a 38-Year-Old Woman With Severe Atopic Dermatitis
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Related Content
